Order
 
HOME
 
Alzheimers
 
Piracetam
 
Idebenone
 
 
 
 
 
 
 
 
 
 
 
 
 
 

































 



Therapeutic efficacy of selegiline (deprenyl)
in neurodegenerative disorders and neurological diseases.

Ebadi M, Brown-Borg H, Ren J, Sharma S,
Shavali S, El ReFaey H, Carlson EC.

Department of Pharmacology
 University of North Dakota
 School of Medicine and Health Sciences
 Grand Forks, ND 58203
Curr Drug Targets. 2006 Nov;7(11):1513-29
 mebadi@medicine.nodak.edu

Abstract

Selegiline inhibits the activity of monoamine oxidase B, enhances the release of dopamine, blocks the uptake of dopamine, acts as a calmodulin antagonist, and enhances the level of cyclic AMP, which in turn protects dopaminergic neurons.  It possesses cognition-enhancing functions, rejuvenates serum insulin-like growth factor I in aged rats, and enhances life expectancy in rodents.  Selegiline possesses neurotrophic-like actions, and rescues axotomized motorneurons independent of monoamine oxidase B inhibition.  It enhances the synthesis of nerve growth factor, protects dopaminergic neurons from glutamate-mediated neurotoxicity, and protects dopaminergic neurons from toxic factors present in the spinal fluid of parkinsonian patients, and the said effect may be mediated via elaborating brain derived neurotrophic factor.  Selegiline increases the striatal superoxide dismutase, protects against peroxynitrite- and nitric oxide-induced apoptosis, and guards dopaminergic neurons from toxicity induced by glutathione depletion.  It stimulates the biosynthesis of interleukin 1-beta and interleukin-6, is an immunoenhancing substance, possesses antiapoptotic actions, and is neuroprotectant in nature. Selegiline has been shown to be efficacious in Parkinson's disease, global ischemia, Gille de la Tourette syndrome, and narcolepsy.  Its therapeutic efficacy in Alzheimer's disease remains uncertain.  In Alzheimer's disease, short term studies of selegiline suggest a beneficial effect; whereas long term studies are less convincing.

Home | Order

  • Deprenyl  in the treatment of Alzheimer's disease
  • Deprenyl  MAO-B inhibitors in the treatment of Alzheimer's disease
  • Deprenyl  for Alzheimer's disease
  • Deprenyl  stimulates biosynthesis of cytokines interleukin-1 & 6
  • Deprenyl  and age-related decline of the striatal dopaminergic system
  • Deprenyl  improves memory in amnesic Alzheimer's patients
  • Deprenyl  treatment of behavioral symptoms of Alzheimer's disease
  • Deprenyl   increases life span in Parkinson's patients
  • Deprenyl   possible mechanisms of action in Parkinson's disease
  • Deprenyl   effect on arm movement in early Parkinson's
  • Deprenyl   effect on cognitive functions in early Parkinson's 
  • Deprenyl   possible mechanisms of action in Parkinson's
  • Deprenyl   depression in Parkinson's disease
  • Deprenyl   improves visuo-motor control in early Parkinsonism
  • Deprenyl   management of early Parkinson's disease
  • Deprenyl   delays the onset of disability in Parkinsonian patients
  • Deprenyl   and tocopherol antioxidative therapy of Parkinsonism
  • Deprenyl   treatment and death of nigral neurons in Parkinson's disease.
  • Deprenyl   rationale for deprenyl medication in Parkinson's disease
  • Deprenyl   and levodopa in Parkinson's disease
  • Deprenyl   is an MAO-B inhibitor
  • Deprenyl   facilitates neuronal growth without inhibiting monoamine oxidase
  • Deprenyl   pharmacology
  • Deprenyl   biochemical actions
  • Deprenyl   effect of MAO-B inhibitors on MPP+ toxicity
  • Deprenyl   the history of its development
  • Deprenyl   protects neurons against neurotoxins
  • Deprenyl   in neurodegenerative disorders
  • Deprenyl   enhances the release of dopamine
  • Deprenyl   plus L-phenylalanine in the treatment of depression
  • Deprenyl   in the treatment-resistant of older depressive patients
  • Deprenyl   effects in atypical depressives
  • Deprenyl   up-regulates superoxide dismutase and catalase
  • Deprenyl   immunostimulant
  • Deprenyl   pharmacology
  • Deprenyl   effect on rat longevity and sexual acitivity
  • Deprenyl   effects of experimental cocaine administration
  • Deprenyl   effects on longevity in animals
  • Deprenyl   effects on subjective ratings of cocaine-induced euphoria
  • Deprenyl   increases the life span in Fischer rats
  • Deprenyl   effects on short term memory in young and aged dogs
  • Deprenyl   the facilitation of dopaminergic activity in the aged brain
  • Deprenyl   fluoxetine (Prozac) and deprenyl
  • Deprenyl   improves cardiac sympathetic terminal function in heart failure
  • Deprenyl   effect on dopamine concentration in the striatum of a primate
  • Deprenyl   a review of the pharmacology
  • Deprenyl   restores IGF-1 levels to young levels
  • Deprenyl   prolongs life in elderly dogs
  • Deprenyl   past, present, and future
  • Deprenyl   relevance to humans
  • Deprenyl   responses of forebrain neurons to deprenyl
  • Deprenyl   protects neurons from glutamate toxicity
  • Deprenyl   nitric oxide production and dilation of cerebral blood vessels
  • Deprenyl   modulates the decline of the striatal dopaminergic system
  • Deprenyl   inhibits tumor growth in rats with mammary tumors
  • Deprenyl   a catecholaminergic activity enhancer in the brain
  • Deprenyl   releases coupling in the catecholaminergic neurons
  • Deprenyl   clinical potential in neurologic and psychiatric disorders
  • Deprenyl   protects human dopaminergic neuroblastoma cells
  • Deprenyl   nitric oxide production and dilation of cerebral blood vessels
  • Deprenyl   assessing the effects of deprenyl on longevity of animals
  • Deprenyl   effects on cocaine-induced euphoria
  • Deprenyl   effects on response to experimental cocaine administration  
  • Deprenyl   Are metabolites of deprenyl useful or harmful?
  • Deprenyl   is devoid of amphetamine-like effects
  • Deprenyl   treated rats lived beyond the known maximum lifespan
  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6
  • Deprenyl   pharmacological basis of the beneficial effects
  • Deprenyl   modulates the decline of the dopamineric system